Off-Label Use of Antidepressant, Anticonvulsant, and Antipsychotic Medications Among Georgia Medicaid Enrollees in 2001.
J Clin Psychiatry 2006;67(6):972-982
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objectives: To determine the prevalence
of and factors associated with the off-label use
of antidepressant, anticonvulsant, and
Method: A retrospective analysis of
Georgia Medicaid recipients was conducted.
Recipients prescribed antidepressant, anticonvulsant, or
antipsychotic medications were identified.
Logistic regression analysis was used to identify
factors associated with off-label use.
Results: A total of 46,976 (75.42%)
antidepressant recipients, 38,497 (80.12%)
anticonvulsant recipients, and 21,252 (63.62%)
antipsychotic recipients received at least 1 of
these medications off-label in 2001. The likelihood
of receiving off-label medications increased
remarkably with advancing age (> = 65 vs. < 65
years: antidepressant: OR = 5.15, 95% CI = 4.76 to
5.56; anticonvulsant: OR = 4.54, 95% CI = 4.16 to
4.96; antipsychotic: OR = 5.21, 95% CI = 4.82 to
5.63). Although receiving new anticonvulsants
launched after 1993 was the strongest predictor
(OR = 7.63, 95% CI = 7.07 to 8.23) of receiving off-label
anticonvulsant medications, exposure to newer antidepressants and antipsychotics did not confer
a higher chance of receiving off-label medications (selective serotonin reuptake inhibitors vs.
tricyclic antidepressants: OR = 0.43, 95% CI = 0.40 to 0.45; atypical vs. conventional antipsychotics: OR = 0.76, 95% CI = 0.72 to 0.80).
Conclusions: The off-label use of
antidepressant, anticonvulsant, and antipsychotic
medications is highly prevalent. Further research
to study the effects of off-label use among this
high risk subpopulation may be an important step
toward defining the scope of and potential for